<DOC>
	<DOCNO>NCT02674906</DOCNO>
	<brief_summary>The primary aim randomize control study determine whether use Anticoagulant Citrate Dextrose Solution -- Formula A ( ACD-A ) cell salvage reduce inflammation oxidative stress cell saver blood compare heparin . The secondary aim determine whether difference activation correlate difference postoperative clinical outcome .</brief_summary>
	<brief_title>Exposure Salvaged Blood Inflammation Oxidative Stress : Effect Different Anticoagulant Regimes ( HECICS )</brief_title>
	<detailed_description>The first primary outcome study difference concentration pro- anti-inflammatory marker marker oxidative stress cell-free fraction centrifugate unwashed autologous blood/anticoagulant mixture cell saver reservoir , correction cardiopulmonary bypass ( CPB ) time start first wash cycle contact time anticoagulant ( either ACD A heparin ) save blood : - total antioxidant status ( TAS ) - Total thiols protein ( TTP ) - oxidize LDL ( oxLDL ) - Pro-inflammatory marker : interleukin ( IL ) , IL-6 , IL-8 , myeloperoxidase ( MPO ) - Anti-inflammatory marker : IL-10 The second primary outcome study difference direct quality wash , salvage red blood cell ( RBC ) : - Blood smear : evaluation light microscopy - Osmotic fragility - Haemoglobin hematocrit - Free haemoglobin - Free iron - Lactate - pH Confounding factor ( CPB duration , contact time anticoagulant save blood , time since first wash cycle case multiple wash cycle ) control . Secondary outcome : The difference concentration pro/anti-inflammatory oxidative stress marker patient plasma preoperatively vs immediately transfusion cell saver blood ( 2 3 hour transfusion extubation transfusion allogenous blood ) . - C-reactive protein ( CRP ) - TAS , TTP - oxLDL - IL-6 , IL-8 , IL-10 - MPO Markers hemolysis patient plasma preoperatively vs immediately pre- post-transfusion salvage RBC ( indirect quality wash salvage RBC ) . - Free Hb - Free iron , ferritin , transferrin - Haptoglobin - Hepcidin</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Elective cardiac revascularization surgery patient : subgroup analysis pump coronary artery bypass grafting ( CABG ) pump CABG ( OPCABG ) Urgent procedure Severe shock Active infection Inflammatory diseases Active neoplasia Immune suppressive drug Active recent renal replacement therapy ( RRT ) Anticoagulation antiaggregation therapy n't timely interrupted accord guideline ( 12,13 ) Need allogenous blood transfusion completion data collection Massive peroperative bleeding safely manage collect study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>